Martin Gauthier
Research Subjects
Martin Gauthier has a total of 128 co-authors. Here are the top co-authors by number of shared publications:
Charlotte Syrykh
Service d’Anatomopathologie Centre Hospitalo‐universitaire (CHU) de Toulouse Institut Universitaire du Cancer de Toulouse‐Oncopole (IUCT‐O) Toulouse France
3 shared publicationsCécile Conte
Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology Toulouse University Hospital, Faculty of Medicine Toulouse France
3 shared publicationsFabien Despas
Clinical Pharmacology Department, Toulouse University Hospital, Toulouse, France
3 shared publicationsLaurent Balardy
3 shared publications- Maryse Lapeyre-Mestre
Faculty of Health University of Toulouse Toulouse France
3 shared publications Camille Laurent
Service d’Anatomopathologie Centre Hospitalo‐universitaire (CHU) de Toulouse Institut Universitaire du Cancer de Toulouse‐Oncopole (IUCT‐O) Toulouse France
2 shared publications
Latest Publications
- Open Access
- 17 July 2026
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 26 (10) , e1187-e1201.e16
Treatment Modalities and the Impact of Granulocyte Colony-Stimulating Factor in AML Patients Treated With Venetoclax and Azacitidine: A DATAML Registry Study
- 17 July 2026
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 26 (10) , e1187-e1201.e16
Open AccessTreatment Modalities and the Impact of Granulocyte Colony-Stimulating Factor in AML Patients Treated With Venetoclax and Azacitidine: A DATAML Registry Study
- Open Access
- 1 October 2024
- Published by AME Publishing Company in AME Clinical Trials Review
- Vol. 2, 90
One more point for ibrutinib plus rituximab over fludarabine, cyclophosphamide and rituximab (FCR)
One more point for ibrutinib plus rituximab over fludarabine, cyclophosphamide and rituximab (FCR)
- 1 October 2024
- Published by AME Publishing Company in AME Clinical Trials Review
- Vol. 2, 90
Open AccessOne more point for ibrutinib plus rituximab over fludarabine, cyclophosphamide and rituximab (FCR)
One more point for ibrutinib plus rituximab over fludarabine, cyclophosphamide and rituximab (FCR)
- 23 August 2023
- Published by Wiley in British Journal of Haematology
- Vol. 203 (2) , 150-151
Vacuolated lymphocytes as initial presentation of angioimmunoblastic T‐cell lymphoma
- 23 August 2023
- Published by Wiley in British Journal of Haematology
- Vol. 203 (2) , 150-151
Vacuolated lymphocytes as initial presentation of angioimmunoblastic T‐cell lymphoma
- 18 March 2022
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 30 (6) , 5431-5440
Impact of the treatment of chronic myeloid leukaemia by tyrosine-kinase inhibitors on sick leaves refund: a nationwide cohort study
Background The advent of chronic myeloid leukaemia (CML) tyrosine-kinase inhibitors (TKI) has led to new paradigms including occupational rehabilitation. Objectives This study aimed to characterize the impact of CML treatment on sick leaves within the 2 years following diagnosis in working-age patients. Methods A cohort of all 18–60-year-old newly diagnosed CML patients initiating a TKI between January 1st 2011 and December 31st 2014 in France was identified in the French National Healthcare database (Système National des Données de Santé [SNDS]). Patients with a sick leave identified in the 24 months after TKI initiation were compared with sex and initiation date matched controls in a nested case–control design. Factors associated with sick leaves were identified through a conditional logistic regression model, providing adjusted odds-ratio (OR) with their 95% confidence interval (CI). Results Among 646 18–60-year-old patients, 268 were prescribed at least one sick leave in the study period, with 176 (27.2%) having their first sick leave prescribed after TKI initiation. The median number of sick days over the 2-years period was 115 per patient (interquartile range 25.5–384.5). In the nested case–control study (176 cases and 176 matched controls), sick leaves were more likely observed with second generation TKI (OR 4.11 [1.80–9.38]), whereas they were less likely observed in case if social deprivation (OR 0.07 [0.02–0.28]. Conclusion More than 25% of working-age CML patients had at least one sick leave within 2 years of TKI initiation, with a higher impact of second generation TKI, and with a median duration of 115 days.
- 18 March 2022
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 30 (6) , 5431-5440
Impact of the treatment of chronic myeloid leukaemia by tyrosine-kinase inhibitors on sick leaves refund: a nationwide cohort study
Background The advent of chronic myeloid leukaemia (CML) tyrosine-kinase inhibitors (TKI) has led to new paradigms including occupational rehabilitation. Objectives This study aimed to characterize the impact of CML treatment on sick leaves within the 2 years following diagnosis in working-age patients. Methods A cohort of all 18–60-year-old newly diagnosed CML patients initiating a TKI between January 1st 2011 and December 31st 2014 in France was identified in the French National Healthcare database (Système National des Données de Santé [SNDS]). Patients with a sick leave identified in the 24 months after TKI initiation were compared with sex and initiation date matched controls in a nested case–control design. Factors associated with sick leaves were identified through a conditional logistic regression model, providing adjusted odds-ratio (OR) with their 95% confidence interval (CI). Results Among 646 18–60-year-old patients, 268 were prescribed at least one sick leave in the study period, with 176 (27.2%) having their first sick leave prescribed after TKI initiation. The median number of sick days over the 2-years period was 115 per patient (interquartile range 25.5–384.5). In the nested case–control study (176 cases and 176 matched controls), sick leaves were more likely observed with second generation TKI (OR 4.11 [1.80–9.38]), whereas they were less likely observed in case if social deprivation (OR 0.07 [0.02–0.28]. Conclusion More than 25% of working-age CML patients had at least one sick leave within 2 years of TKI initiation, with a higher impact of second generation TKI, and with a median duration of 115 days.
- 8 March 2022
- Published by Wiley in Hematological Oncology
- Vol. 40 (4) , 805-808
“Accelerated phase” chronic lymphocytic leukemia: Still an intermediate risk disease in the era of targeted therapies
- 8 March 2022
- Published by Wiley in Hematological Oncology
- Vol. 40 (4) , 805-808
“Accelerated phase” chronic lymphocytic leukemia: Still an intermediate risk disease in the era of targeted therapies
- 6 March 2022
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 44 (5) , 815-816
Look beyond the plasma cells in immunocompromised patients
- 6 March 2022
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 44 (5) , 815-816
Look beyond the plasma cells in immunocompromised patients
- 17 February 2022
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 43 (6) , 356-364
La leucémie lymphoïde chronique
- 17 February 2022
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 43 (6) , 356-364
La leucémie lymphoïde chronique
- Open Access
- 7 October 2021
- Published by American Society of Hematology in Blood Advances
- Vol. 5 (19) , 3862-3872
Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA study
Primary mediastinal B-cell lymphoma (PMBL) is a rare type of aggressive lymphoma typically affecting young female patients. The first-line standard of care remains debated. We performed a large multicenter retrospective study in 25 centers in France and Belgium to describe PMBL patient outcomes after first-line treatment in real-life settings. A total of 313 patients were enrolled and received rituximab (R) plus ACVBP (doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone) (n = 180) or CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) delivered every 14 days (R-CHOP14, n = 76) or 21 days (R-CHOP21, n = 57) and consolidation strategies in modalities that varied according to time and institution, mainly guided by positron emission tomography. Consolidation autologous stem cell transplantation was performed for 46 (25.6%), 24 (31.6%), and 1 (1.8%) patient in the R-ACVBP, R-CHOP14, and R-CHOP21 groups, respectively (P < .001); only 17 (5.4%) patients received mediastinal radiotherapy. The end-of-treatment complete metabolic response rates were 86.3%, 86.8%, and 76.6% (P = .23) in the R-ACVBP, R-CHOP14, and R-CHOP21 groups. The median follow-up was 44 months, and the R-ACVBP, R-CHOP14, and R-CHOP21 three-year progression-free survival probabilities were 89.4% (95% confidence interval [CI], 84.8-94.2), 89.4% (95% CI, 82.7-96.6), and 74.7% (95% CI, 64-87.1) (P = .018). A baseline total metabolic tumor volume (TMTV) ≥360 cm3 was associated with a lower progression-free survival (hazard ratio, 2.18; 95% CI, 1.05-4.53). Excess febrile neutropenia (24.4% vs 5.3% vs 5.3%; P < .001) and mucositis (22.8% vs 3.9% vs 1.8%; P < .001) were observed with R-ACVBP compared with the R-CHOP regimens. Patients with PMBL treated with dose-dense immunochemotherapy without radiotherapy have excellent outcomes. R-ACVBP acute toxicity was higher than that of R-CHOP14. Our data confirmed the prognostic importance of baseline TMTV.
- 7 October 2021
- Published by American Society of Hematology in Blood Advances
- Vol. 5 (19) , 3862-3872
Open AccessOutcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA study
Primary mediastinal B-cell lymphoma (PMBL) is a rare type of aggressive lymphoma typically affecting young female patients. The first-line standard of care remains debated. We performed a large multicenter retrospective study in 25 centers in France and Belgium to describe PMBL patient outcomes after first-line treatment in real-life settings. A total of 313 patients were enrolled and received rituximab (R) plus ACVBP (doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone) (n = 180) or CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) delivered every 14 days (R-CHOP14, n = 76) or 21 days (R-CHOP21, n = 57) and consolidation strategies in modalities that varied according to time and institution, mainly guided by positron emission tomography. Consolidation autologous stem cell transplantation was performed for 46 (25.6%), 24 (31.6%), and 1 (1.8%) patient in the R-ACVBP, R-CHOP14, and R-CHOP21 groups, respectively (P < .001); only 17 (5.4%) patients received mediastinal radiotherapy. The end-of-treatment complete metabolic response rates were 86.3%, 86.8%, and 76.6% (P = .23) in the R-ACVBP, R-CHOP14, and R-CHOP21 groups. The median follow-up was 44 months, and the R-ACVBP, R-CHOP14, and R-CHOP21 three-year progression-free survival probabilities were 89.4% (95% confidence interval [CI], 84.8-94.2), 89.4% (95% CI, 82.7-96.6), and 74.7% (95% CI, 64-87.1) (P = .018). A baseline total metabolic tumor volume (TMTV) ≥360 cm3 was associated with a lower progression-free survival (hazard ratio, 2.18; 95% CI, 1.05-4.53). Excess febrile neutropenia (24.4% vs 5.3% vs 5.3%; P < .001) and mucositis (22.8% vs 3.9% vs 1.8%; P < .001) were observed with R-ACVBP compared with the R-CHOP regimens. Patients with PMBL treated with dose-dense immunochemotherapy without radiotherapy have excellent outcomes. R-ACVBP acute toxicity was higher than that of R-CHOP14. Our data confirmed the prognostic importance of baseline TMTV.